fda warning letter bpc-157 peptide compounding safety Exciting news for peptides coming out of today's committee hearing! The FDA's Overreach on Compounded Peptides

AOD-9604 was subsequently placed in Category 2 of the bulk drug substance nomination list, then later withdrawn from that nomination in April 2026

Did not experience any weight loss, unfortunately

The 2025 NEJM trial comparing tirzepatide directly against semaglutide showed 20.2% versus 13.7% weight loss over the same treatment period

IV drips replenish hydration, electrolytes, vitamins, amino acids, and metabolic compounds like NAD+ or glutathione

Understanding why this occursfrom metabolic adjustment and nutrient demands to injection site reactionshelps distinguish expected responses from complications requiring medical attention

Eat a meal or light snack before your appointment